Physician profile
Robert B Posnick
NPI 1497866388
$951,469.20
in general payments reported to CMS, 2019-2025
32 companies · $142K in 2025
The $142K reported for 2025 was more than what 98% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141K · 2020: $59K · 2021: $90K · 2022: $153K · 2023: $185K · 2024: $182K · 2025: $142K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $370K · Travel and Lodging: $57K · Food and Beverage: $34K · Consulting Fee: $34K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $13K · Education: $729 · Honoraria: $8.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $369,542.43 |
| Travel and Lodging | $56,774.65 |
| Food and Beverage | $34,403.47 |
| Consulting Fee | $34,020.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $12,996.00 |
| Education | $728.98 |
| Honoraria | $8.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $317,702.07 | 2019-2025 | Otezla, Otezla, Lumakras |
| Abbvie INC. | $137,461.21 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $93,268.42 | 2019-2025 | Ilumya |
| Incyte Corporation | $62,676.22 | 2021-2025 | Opzelura, Opzelura |
| Pfizer INC. | $56,078.49 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $51,002.70 | 2021-2025 | Sotyktu |
| Ucb, INC. | $48,364.65 | 2019-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $46,640.51 | 2021-2025 | Nemluvio, Aklief |
| Celgene Corporation | $35,916.95 | 2019 | |
| Janssen Scientific Affairs, LLC | $32,135.91 | 2019-2024 | Tremfya |
| Novartis Pharmaceuticals Corporation | $31,645.17 | 2019-2025 | Cosentyx |
| Genzyme Corporation | $12,093.43 | 2019-2025 | |
| Lilly USA, LLC | $10,075.06 | 2019-2025 | Ebglyss, Olumiant, Taltz |
| Leo Pharma INC. | $3,920.73 | 2019-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $2,674.81 | 2019-2025 | Tremfya |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $1,783.16 | 2022-2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,774.38 | 2021-2023 | |
| Botanix Sb INC | $1,674.18 | 2025 | Sofdra |
| Arcutis Biotherapeutics, INC. | $1,351.92 | 2023-2025 | Zoryve |
| Sanofi-Aventis U.S. LLC | $1,228.14 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $684.59 | 2019-2025 | Dupixent |
| Organon LLC | $331.89 | 2024-2025 | Vtama |
| Mayne Pharma Commercial LLC | $268.63 | 2019-2021 | |
| Vyne Pharmaceuticals INC. | $244.63 | 2020-2021 | |
| Genentech USA, INC. | $212.24 | 2020-2022 | |
| Helsinn Therapeutics (U.S.), INC. | $102.59 | 2019-2022 | |
| Regeneron Pharmaceuticals, INC. | $67.90 | 2023-2025 | Dupixent |
| Dermira, INC. | $38.35 | 2019 | |
| Biofrontera INC. | $19.36 | 2021 | |
| Strata Skin Sciences, INC. | $17.30 | 2021 | |
| Smith+Nephew, INC. | $13.61 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Posnick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.